Published in Glycoconj J on January 07, 2016
Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. Oncotarget (2016) 0.75
What is new in CDG? J Inherit Metab Dis (2017) 0.75
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods (2012) 4.93
The glycosylation of hemoglobin: relevance to diabetes mellitus. Science (1978) 3.87
Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell (2010) 3.60
Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A (2003) 3.13
POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet (2005) 2.80
Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med (2014) 2.62
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 2.45
Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res (2009) 2.39
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med (2004) 2.29
Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res (2009) 2.20
Correction of leukocyte adhesion deficiency type II with oral fucose. Blood (1999) 2.13
Glycoproteomics based on tandem mass spectrometry of glycopeptides. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.99
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
Congenital disorders of glycosylation. Ann N Y Acad Sci (2010) 1.93
Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virchows Arch (1998) 1.91
Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum Mol Genet (2012) 1.90
Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome. Clin Chim Acta (1984) 1.83
Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer (2006) 1.82
Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics (2009) 1.79
Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet (2014) 1.73
Glycans as cancer biomarkers. Biochim Biophys Acta (2011) 1.66
Analysis of protein glycosylation by mass spectrometry. Nat Protoc (2007) 1.65
Characterization of glycopeptides by combining collision-induced dissociation and electron-transfer dissociation mass spectrometry data. Rapid Commun Mass Spectrom (2009) 1.60
Congenital disorders of glycosylation (CDG): it's (nearly) all in it! J Inherit Metab Dis (2011) 1.59
CDG nomenclature: time for a change! Biochim Biophys Acta (2009) 1.49
Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. Anal Chem (2004) 1.47
Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J Chromatogr A (2004) 1.42
Glycosylation of serum proteins in inflammatory diseases. Dis Markers (2008) 1.39
Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin Chem (2001) 1.38
PIG-M transfers the first mannose to glycosylphosphatidylinositol on the lumenal side of the ER. EMBO J (2001) 1.34
Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One (2010) 1.34
Novel glycan biomarkers for the detection of lung cancer. J Proteome Res (2011) 1.33
Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology (2003) 1.32
Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res (2008) 1.29
Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap--Fourier transform mass spectrometry. Glycobiology (2006) 1.28
Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochim Biophys Acta (2012) 1.28
Congenital disorders of glycosylation: new defects and still counting. J Inherit Metab Dis (2014) 1.26
The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochim Biophys Acta (2008) 1.25
N- and O-glycosylation in the murine synaptosome. Mol Cell Proteomics (2013) 1.21
Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics (2008) 1.21
De novo sequencing and homology searching. Mol Cell Proteomics (2011) 1.21
Effective use of mass spectrometry for glycan and glycopeptide structural analysis. Anal Chem (2012) 1.20
Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis (2012) 1.19
How to find and diagnose a CDG due to defective N-glycosylation. J Inherit Metab Dis (2011) 1.18
Targeted therapy for inherited GPI deficiency. N Engl J Med (2007) 1.17
N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol Cell Proteomics (2007) 1.15
Congenital disorders of glycosylation: a review. Pediatr Res (2002) 1.15
Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med (2014) 1.14
Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res (2011) 1.13
The role of protein glycosylation in Alzheimer disease. FEBS J (2013) 1.12
Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.11
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab (2003) 1.10
Improved HPLC method for carbohydrate-deficient transferrin in serum. Clin Chem (2003) 1.09
Glycomics using mass spectrometry. Glycoconj J (2012) 1.06
Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal Chem (2013) 1.06
Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Clin Chem (2011) 1.05
Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl (2010) 1.03
Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol (2013) 1.03
The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj J (2012) 1.02
Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol Metab Clin North Am (2001) 1.02
Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol Cancer Ther (2013) 1.01
Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry. Mol Cell Proteomics (2011) 1.01
Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Anal Biochem (2013) 1.00
A rapid mass spectrometric strategy for the characterization of N- and O-glycan chains in the diagnosis of defects in glycan biosynthesis. Proteomics (2007) 1.00
Analyses of dolichol pyrophosphate-linked oligosaccharides in cell cultures and tissues by fluorophore-assisted carbohydrate electrophoresis. Glycobiology (2002) 1.00
A kinetic study of the isozymes determined by the three human phosphoglucomutase loci PGM1, PGM2, and PGM3. Eur J Biochem (1974) 0.98
Fucosylated glycoproteins as markers of liver disease. Dis Markers (2008) 0.98
Diagnosis of congenital disorders of glycosylation by capillary zone electrophoresis of serum transferrin. Clin Chem (2003) 0.97
Inherited glycosylphosphatidyl inositol deficiency: a treatable CDG. Biochim Biophys Acta (2009) 0.95
Diagnostic serum glycosylation profile in patients with intellectual disability as a result of MAN1B1 deficiency. Brain (2014) 0.95
Use of CID/ETD mass spectrometry to analyze glycopeptides. Curr Protoc Protein Sci (2012) 0.93
Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J Pediatr (1999) 0.92
Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One (2013) 0.92
Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients. Biochim Biophys Acta (2009) 0.92
Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology (2014) 0.92
Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity. Biochim Biophys Acta (1999) 0.92
Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG. Glycoconj J (2012) 0.90
Glycopeptide enrichment and separation for protein glycosylation analysis. J Sep Sci (2012) 0.90
Transferrin and apolipoprotein C-III isofocusing are complementary in the diagnosis of N- and O-glycan biosynthesis defects. Clin Chem (2006) 0.90
Tissue-Specific Glycosylation at the Glycopeptide Level. Mol Cell Proteomics (2015) 0.89
The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation. J Inherit Metab Dis (2011) 0.88
Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/phenotype correlation. Am J Med Genet (2002) 0.87
Glycosylation as a marker for inflammatory arthritis. Cancer Biomark (2014) 0.87
Mass spectrometry for congenital disorders of glycosylation, CDG. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.87
Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes (2012) 0.87
α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol Med (2013) 0.87
Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging (1996) 0.87
Confident assignment of site-specific glycosylation in complex glycoproteins in a single step. J Proteome Res (2014) 0.87
Congenital disorders of glycosylation and intellectual disability. Dev Disabil Res Rev (2013) 0.87
Transferrin: evidence for two common subtypes of the TfC allele. Hum Genet (1978) 0.87
Thyroid function tests and characterization of thyroxine-binding globulin in the carbohydrate-deficient glycoprotein syndrome type I. J Clin Endocrinol Metab (1995) 0.86
Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res (2014) 0.86
Automated measurement of permethylated serum N-glycans by MALDI-linear ion trap mass spectrometry. Carbohydr Res (2009) 0.85
Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. Glycobiology (2012) 0.85
Large-Scale Measurement of Absolute Protein Glycosylation Stoichiometry. Anal Chem (2015) 0.84
Characterization of transferrin glycoforms in human serum by CE-UV and CE-ESI-MS. Electrophoresis (2007) 0.84
Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochim Biophys Acta (2014) 0.83
Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum (2008) 0.82
Afamin--A pleiotropic glycoprotein involved in various disease states. Clin Chim Acta (2015) 0.81